angiotensin II   Click here for help

GtoPdb Ligand ID: 2504

Synonyms: ang II | Giapreza®
Approved drug
angiotensin II is an approved drug (FDA (2017))
Comment: Endogenous angiotensin II is a vasopressor.
Species: Human, Mouse, Rat
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: angiotensin ii

2D Structure
Click here for help
Click here for structure editor
Click here for help
Canonical SMILES CCC(C(C(=O)NC(C(=O)N1CCCC1C(=O)NC(C(=O)O)Cc1ccccc1)Cc1nc[nH]c1)NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CC(=O)O)N)CCCN=C(N)N)Cc1ccc(cc1)O)C
Isomeric SMILES CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)Cc1nc[nH]c1)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCN=C(N)N)Cc1ccc(cc1)O)C
InChI InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
1. Czirják G, Fischer T, Spät A, Lesage F, Enyedi P. (2000)
TASK (TWIK-related acid-sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II.
Mol Endocrinol, 14 (6): 863-74. [PMID:10847588]
2. de Gasparo M, Whitebread S, Bottari SP, Levens NR. (1994)
Heterogeneity of angiotensin receptor subtypes.  In  Medicinal Chemistry of the Renin-Angiotensin System.
Edited by Timmermanns PBMWM, Wexler RR (Elsevier) 269-294. [ISBN:0444820531]
3. Goto Y, Hattori A, Ishii Y, Mizutani S, Tsujimoto M. (2006)
Enzymatic properties of human aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV.
J Biol Chem, 281 (33): 23503-13. [PMID:16790432]
4. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C et al.. (2017)
Angiotensin II for the Treatment of Vasodilatory Shock.
N Engl J Med, 377 (5): 419-430. [PMID:28528561]
5. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournié-Zaluski MC, Roques BP. (1996)
The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A.
Peptides, 17 (4): 601-7. [PMID:8804068]
6. Smith RD, Timmermans PB. (1994)
Human angiotensin receptor subtypes.
Curr Opin Nephrol Hypertens, 3 (1): 112-22. [PMID:7850406]
7. Vanderheyden PM, Fierens FL, De Backer JP, Fraeyman N, Vauquelin G. (1999)
Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
Br J Pharmacol, 126 (4): 1057-65. [PMID:10193788]
8. Whitebread S, Mele M, Kamber B, de Gasparo M. (1989)
Preliminary biochemical characterization of two angiotensin II receptor subtypes.
Biochem Biophys Res Commun, 163 (1): 284-91. [PMID:2775266]
9. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. (1996)
Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.
Proc Natl Acad Sci USA, 93 (21): 11968-73. [PMID:8876246]